Rexlemestrocel-L
- Generic Name
- Rexlemestrocel-L
- Drug Type
- Biotech
- CAS Number
- 2172954-10-6
- Unique Ingredient Identifier
- 4LS0IJZ59V
- Background
Rexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product. It is being investigated in various cardiac conditions, such as chronic heart failure and acute myocardial infarction.
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- Drug: Saline
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06325566
- Locations
- ๐บ๐ธ
Boomerang Health Care, Concord, California, United States
๐บ๐ธColorado Spine Partners/The Denver Spine and Pain Institute, Greenwood, Colorado, United States
๐บ๐ธEximia EquiHealth Research LLC, Durham, North Carolina, United States
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 404
- Registration Number
- NCT02412735
- Locations
- ๐บ๐ธ
Tennessee Valley Pain Consultants, Huntsville, Alabama, United States
๐บ๐ธIntegrated Pain Management, Walnut Creek, California, United States
๐บ๐ธHoly Cross Orthopedics Institute, Oakland Park, Florida, United States
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFฮฑ Inhibitor
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01851070
- Locations
- ๐บ๐ธ
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธArthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States
๐บ๐ธUCLA, Los Angeles, California, United States
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT01576328
- Locations
- ๐บ๐ธ
SC Clinical Research, Garden Grove, California, United States
๐บ๐ธPennington Biomedical Research Center, Baton Rouge, Louisiana, United States
๐บ๐ธBig Sky Clinical Research, Butte, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.